Scaling a Peptide Brand to $100k/Month

$100k/month sounds like a marketing goal. it's actually an arithmetic problem with three inputs: average order value, new customer volume, and repeat rate. once you write it out, the strategy stops being abstract and becomes a list of specific things to fix. most brands that plateau below $100k are failing on exactly one of the three, and they usually can't tell which because they're looking at ROAS instead of the underlying mechanics.

the arithmetic first

take a peptide brand with a $180 average order value. $100,000 / $180 = 556 orders per month. that's the whole target. now split it.

• —with a 0% repeat rate: you need 556 new customers every single month, forever, and the number goes up as you scale because you're constantly replacing everyone.
• —with a 35% repeat rate: roughly 195 of those orders come from existing customers, so you need about 361 new customers.
• —with a 55% repeat rate (achievable with a subscription or refill product): ~306 repeat orders, ~250 new customers needed.

at a $70 CAC, 361 new customers costs about $25,300 in ad spend. against $100,000 in revenue that's a 3.95 blended ROAS — a healthy, real business. at a 0% repeat rate the same math needs $38,900 in spend, a 2.57 blended ROAS, and the business is far more fragile. the repeat rate is doing more work than any media buying decision you will ever make.

361 customers a month is roughly 12 a day. framed that way it stops feeling like a moonshot and starts feeling like an operations target. that reframe matters, because the tactics that get you 12 orders a day are boring and repeatable, while the tactics people imagine for '$100k/month' are usually a hunt for a magic ad.

the four plateaus and what breaks at each

plateau one: $0–$15k/month — offer validation

if you're stuck here, the problem is almost never traffic. it's that the offer doesn't convert. check site conversion rate first: under 1.5% on warm-ish traffic means the product page, price, or reason-to-believe is wrong. fix sequence: clarify what the product does and who it's for, make the price legible against alternatives, add real proof (provider on camera, third-party testing, COAs), and reduce the number of decisions at checkout. do not increase spend to escape this plateau — you'll just lose money faster.

plateau two: $15k–$40k/month — creative volume

this is the most common wall and the most misdiagnosed. you found two or three ads that worked, you scaled them, they fatigued, and now performance decays every week while you make one new ad every ten days. the media buyer isn't the problem. the pipeline is.

the fix is unglamorous: get to 15–30 net-new creative assets per month, across genuinely different angles rather than color variations of the same concept. angles that work in this category include the provider explaining the mechanism, a patient telling a specific before-and-after story within platform rules, the sourcing and testing story, a direct price/value comparison, a myth-correction format, and the founder's origin story. each of those is a different psychological entry point, not a different thumbnail.

for scale context: livv well was running 294 live ads during their growth phase, and the top performers landed between 6.79 and 14.96 ROAS. you don't find a 14x ad by making four ads. you find it by making 100 and letting the account tell you. ac-nextgen had a single creative return $53,269 on $6,049 in spend; goodscience had one return $33,225 on $8,664. those outliers exist inside a large pool of tested creative — they are not the result of one brilliant idea, and they are not typical outcomes you should plan a budget around.

plateau three: $40k–$70k/month — economics

here the ads work but the business doesn't compound. usually one of three things: CAC crept up as you scaled and nobody re-ran the math, contribution margin is thinner than you think because you never fully loaded shipping and processing, or your repeat rate is near zero and you're on an acquisition treadmill.

• —recompute contribution margin per order with everything loaded: COGS, inbound freight, 3PL pick/pack, shipping, payment processing (high-risk rates are often 3.5–6%, not 2.9%), and refunds/chargebacks.
• —if contribution margin per order is under ~55%, raise price or bundle before you touch ads. a $30 AOV increase does more for this business than a 10% CAC improvement.
• —build the reorder machine: refill reminder timed to actual usage cycle, subscribe-and-save with a real discount, a second product that pairs naturally with the first.
• —look at 60- and 90-day LTV per cohort, not just first-order value. if cohort 3 has a better 90-day LTV than cohort 1, you can afford a higher CAC than you think.

plateau four: $70k–$100k/month — operations and channel concentration

at this level the constraints become structural. stockouts start costing real money. a single merchant account is now a genuine business risk. customer support volume outgrows whoever was answering emails between other tasks. and if 95% of revenue comes from one meta ad account, one restriction takes your business to zero for a week.

• —second merchant account, live and processing a share of volume, not sitting dormant.
• —inventory planning against a 90-day forward forecast with real safety stock.
• —dedicated support with documented responses for the questions that are actually clinical in nature, escalated appropriately.
• —a second acquisition channel started — email is already there, but consider organic/creator content and, if you have a clinic, in-person to online conversion.
• —a second product. it raises AOV, improves repeat, and gives your creative team new angles.

the creative engine, specifically

since creative volume is the most common constraint, here's what a functioning engine looks like operationally rather than in theory.

1. 1.maintain an angle bank — a written list of 10–15 distinct positioning angles for your product. this is the source material, and it's a strategy document, not a creative one.
2. 2.produce in batches. one shoot day with a provider generates 20+ assets. one creator brief sent to five creators generates 15 videos. batching is how volume becomes affordable.
3. 3.hook-first editing. most testing should be new hooks on proven bodies. a hook change is 20 minutes of editing and often the entire difference in performance.
4. 4.test at a defined budget per creative so results are comparable — pick a number that gets you enough conversions to read, and hold it constant.
5. 5.kill fast and document why. an angle that failed is information, not waste. write it down or you'll test it again in four months.
6. 6.keep winners in rotation and refresh them with new openings before they fully fatigue, rather than after.

at scale, the account isn't limited by the media buyer's skill. it's limited by how many good ideas reach the account each week.

what scaling spend actually looks like

the mechanical part is simpler than most people expect. increase budget 20–30% at a time on proven performers and hold for 48–72 hours before the next increase. consolidate rather than fragment — a few well-funded campaigns generally learn better than dozens of underfunded ones. keep a permanent testing budget of roughly 20–30% of total spend regardless of how well the winners are doing, because the day you stop testing is the day your decay clock starts.

and watch blended, not platform-reported. platform ROAS routinely overstates by 20–60% depending on attribution window. blended is total revenue divided by total ad spend for the period, and it's the only number that reconciles with your bank account. wayyless ran $4.3M in spend to $19.1M in revenue — a 4.45 blended ROAS — and that's the shape of a business that scaled without lying to itself. it's also a different business with a different offer; your numbers will differ.

the retention layer most peptide brands skip

email and sms should be producing 25–35% of total revenue by the time you're at $100k/month. if it's under 15%, you have found free money. the flows that matter, in order of impact:

• —refill reminder timed to the actual product usage cycle. if a vial lasts 30 days, the reminder lands at day 22 — not day 30 when they've already run out and started shopping.
• —post-purchase education sequence. reduces refunds, reduces support tickets, increases reorder because the customer actually uses the product correctly.
• —abandoned checkout — in this category, hesitation is usually about trust and legitimacy, so the recovery email should address sourcing, testing, and medical oversight rather than offering a discount.
• —winback at 45 and 75 days past expected reorder.
• —cross-sell into a second product once the first is established.

and if you're a med spa, the in-clinic to online bridge is the highest-ROI thing on this list and almost nobody does it properly. every patient who walks out of a treatment room should have a reason and a mechanism to reorder at home. that's not a marketing campaign, it's a checkout-counter process.

one honest caveat on all of the above: these are mechanics, not promises. the numbers in this article come from real accounts, and they depend on offer, price point, market, brand strength, capital, and execution speed. plenty of brands run this playbook and land at $40k/month instead of $100k. none of this is financial advice.